Physician profile
Barbara Clayson
NPI 1518102573
$1,593.32
in general payments reported to CMS, 2019-2025
12 companies · $642 in 2025
The $642 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $126 · 2022: $229 · 2023: $357 · 2024: $240 · 2025: $642.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,238.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $405.33 | 2021-2025 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $285.73 | 2024-2025 | Uzedy, Austedo Xr |
| Abbvie INC. | $262.63 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $204.89 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $163.54 | 2023-2025 | Rexulti, Abilify Maintena |
| E.R. Squibb & Sons, L.L.C. | $109.79 | 2025 | Cobenfy |
| Lundbeck LLC | $53.87 | 2025 | Rexulti |
| Brainsway USA INC | $30.01 | 2025 | Deep Tms System |
| Alkermes, INC. | $22.60 | 2025 | Lybalvi |
| Corium, LLC | $22.03 | 2024 | Azstarys |
| Vanda Pharmaceuticals INC. | $17.21 | 2025 | Hetlioz, Fanapt |
| Axsome Therapeutics, INC. | $15.69 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Clayson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.